QUOTE AND NEWS
FierceBiotech  Jun 29  Comment 
Sarepta, ending a protracted process that may have cost its last CEO his job, submitted its treatment for Duchenne muscular dystrophy to the FDA, setting the stage for a possible approval early next year.
TheStreet.com  Jun 22  Comment 
NEW YORK (TheStreet) -- Shares of BioMarin Pharmaceutical were gaining 0.2% to $138.17 on light trading volume on Monday afternoon. On Wednesday, analyst firm SunTrust Robinson Humphrey increased its price target for the biotechnology company...
Benzinga  Jun 19  Comment 
Baird downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Outperform to Neutral. BioMarin Pharmaceutical shares have gained 109.81 percent over the past 52 weeks, while the S&P 500 index has surged 8.07 percent in the same...
TheStreet.com  Jun 19  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Aerie Pharmaceuticals was upgraded to buy from hold by Canaccord Genuity, which set a 12-month price target of $40. After much anticipation, Aerie's interactions with the Food and Drug Administration...
Benzinga  Jun 18  Comment 
Thursday’s market session contained many exciting stock movements. Gainers Fitbit Inc (NYSE: FIT) was introduced to the New York Stock Exchange, opening at the price of $30.20, representing a 52 percent spike. Kroger Co (NYSE: KR)...
Benzinga  Jun 18  Comment 
Toward the end of trading Thursday, the Dow traded up 1.13 percent to 18,138.10 while the NASDAQ climbed 1.32 percent to 5,131.69. The S&P also rose, gaining 1.03 percent to 2,121.97. Leading and Lagging Sectors Healthcare sector was the...
Forbes  Jun 18  Comment 
In trading on Thursday, the PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE) is outperforming other ETFs, up about 3.4% on the day. Components of that ETF showing particular strength include shares of Biomarin Pharma (BMRN), up about...
TheStreet.com  Jun 18  Comment 
NEW YORK (TheStreet) -- Biotech stocks are higher on Thursday, led by BioMarin Pharmaceutical and Radius Health , up 12% and 18%, respectively.  On CNBC's "Mad Dash" segment, TheStreet's Jim Cramer pointed out BioMarin received a slew of...
MarketWatch  Jun 18  Comment 
Shares of BioMarin Pharmaceuticals leapt by more than 10% in early trading Thursday after the biotechnology company reported a 50% improvement in growth velocity for children being treated with an experimental treatment for human dwarfism. The...
newratings.com  Jun 18  Comment 
WASHINGTON (dpa-AFX) - Arrowhead Research Corp. (ARWR) has received regulatory clearance in Germany for two additional phase 2b multiple-dose studies of ARC-520 in patients with chronic HBV infection to be conducted in parallel. The studies,...




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki